title: Exenatide for the treatment of type 2 diabetes mellitus.
abstract: Exenatide is a glucagon-like peptide-1 agonist. It is being investigated as an add-on therapy for patients with type 2 diabetes mellitus who are taking oral antidiabetic drugs. Evidence indicates that exenatide reduces glycosylated hemoglobin and plasma glucose levels when compared with placebo. Limitations of the therapy include the need for twice daily injections and potentially dose-limiting nausea and vomiting. Long-term studies are required to determine the effects of exenatide on disease-related morbidity and mortality.
authors.forename: B
authors.initials: B
authors.lastname: Ruddock
mesh_terms: D001786:Blood Glucose / Q000187:drug effects; D002170:Canada; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D052216:Glucagon-Like Peptide 1 / Q000008:administration & dosage / Q000009:adverse effects / Q000819:agonists / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007328:Insulin; D016032:Randomized Controlled Trials as Topic
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D052216:Glucagon-Like Peptide 1